Psychosocial care for children receiving chimeric antigen receptor (CAR) T-cell therapy

Pediatr Blood Cancer. 2020 May;67(5):e28249. doi: 10.1002/pbc.28249. Epub 2020 Mar 11.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). However, this new paradigm has introduced unique considerations specific to the patients receiving CAR T-cell therapy, including prognostic uncertainty, symptom management, and psychosocial support. With increasing availability, there is a growing need for evidence-based recommendations that address the specific psychosocial needs of the children who receive CAR T-cell therapy and their families. To guide and standardize the psychosocial care offered for patients receiving CAR T-cell therapy, we propose the following recommendations for addressing psychosocial support.

Keywords: acute lymphoblastic leukemia; chimeric antigen receptor t-cell; communication; interdisciplinary care; palliative care; pediatric oncology; psychosocial; symptom management.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Review

MeSH terms

  • Child
  • Humans
  • Immunotherapy, Adoptive / psychology*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / psychology*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Receptors, Chimeric Antigen*

Substances

  • Receptors, Chimeric Antigen